[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
March 2016

Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non–Small Cell Lung Cancer

Author Affiliations
  • 1Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei
  • 2Department of Oncology, National Taiwan University Hospital, Taipei
  • 3Department of Urology, National Taiwan University College of Medicine, Taipei
  • 4Department of Surgery, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City
JAMA Dermatol. 2016;152(3):340-342. doi:10.1001/jamadermatol.2015.4448

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used to treat non–small cell lung cancer. Four major skin toxic effects with different incidences have been reported from clinical studies, including acneiform eruption (60%-94%), pruritus (16%-60%), xerosis (4%-38%), and paronychia (6%-12%).1,2 However, a direct comparison of the incidences and severities of the 4 types of skin toxic effects for 3 different EGFR-TKIs in the same patient cohort has been lacking to date.

First Page Preview View Large
First page PDF preview
First page PDF preview
×